Evidence map›Paper›PMID 28459958›Full record

Trial reportEuropean heart journal2017

Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).

Peter S Pang, Javed Butler, Sean P Collins, Gad Cotter, Beth A Davison, Justin A Ezekowitz, Gerasimos Filippatos, Phillip D Levy, Marco Metra, Piotr Ponikowski and 6 more

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. β-Arrestin-2 Regulates Sodium Taste Processing.Hypertension (Dallas, Tex. : 1979) · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Agonism and Biased Signaling.Handbook of experimental pharmacology · 2026
    Review
  14. Article
  15. Future Directions in GPCR Biased Signaling and Ligand Pharmacology.Handbook of experimental pharmacology · 2026
    Review
  16. Renin-angiotensin-aldosterone system and its relation to hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Review
  17. Review
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 6 countries.

Peter S PangDepartment of Emergency Medicine, Indiana University School of Medicine & Indianapolis EMS, Indianapolis, IN, USA.
Javed ButlerSUNY Stonybrook School of Medicine, New York, NY, USA.
Sean P CollinsVanderbilt University, Nashville, TN, USA.
Gad CotterMomentum Research Inc., Durham, NC, USA.
Beth A DavisonMomentum Research Inc., Durham, NC, USA.
Justin A EzekowitzUniversity of Alberta, Edmonton, Alberta, Canada.
Gerasimos FilippatosNational and Kapodistrian University of Athens, School of Medicine, Heart Failure Unit, Department of Cardiology, Attikon University Hospital, Athens, Greece.
Phillip D LevyWayne State University School of Medicine and Cardiovascular Research Institute, Detroit, MI, USA.
Marco MetraCardiology, University of Brescia, Brescia, Italy.
Piotr PonikowskiClinical Military Hospital, Medical University, Wroclaw, Poland.
John R TeerlinkSection of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA.
Adriaan A VoorsUniversity of Groningen, Groningen, the Netherlands.
David BharuchaAllergan plc (Forest Labs), Jersey City, NJ, USA.
Kathleen GoinTrevena Inc, King of Prussia, PA, USA.
David G SoergelTrevena Inc, King of Prussia, PA, USA.
G Michael FelkerDuke University School of Medicine and the Duke Clinical Research Institute, Durham, NC, USA.
Momentum Research · USAllergan (United States) · USDuke University · USIndiana University – Purdue University Indianapolis · USNational and Kapodistrian University of Athens · GRStony Brook School · USUniversity of Alberta · CAUniversity of Brescia · ITUniversity of California, San Francisco · USUniversity of Groningen · NLVanderbilt University · USWayne State University · USWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCurrently, no acute heart failure (AHF) therapy definitively improves outcomes. Reducing morbidity and mortality from acute heart failure (AHF) remains an unmet need. TRV027 is a novel 'biased' ligand of the angiotensin II type 1 receptor (AT1R), selectively antagonizing the negative effects of angiotensin II, while preserving the potential pro-contractility effects of AT1R stimulation. BLAST-AHF was designed to determine the safety, efficacy, and optimal dose of TRV027 to advance into future studies. METHODS AND

resultsBLAST-AHF was a multi-centre, international, randomized, double-blind, placebo-controlled, parallel group, phase IIb dose-ranging study, enrolling patients with AHF into 4 groups: placebo, 1, 5, or 25 mg/h of TRV027. Treatment was by IV infusion for 48-96 h. The primary composite endpoint was comprised of the following: (i) time from baseline to death through day 30, (ii) time from baseline to heart failure re-hospitalization through day 30, (iii) the first assessment time point following worsening heart failure through day 5, (iv) change in dyspnea visual analogue scale (VAS) score calculated as the area under the curve (AUC) representing the change from baseline over time from baseline through day 5, and (v) length of initial hospital stay (in days) from baseline. Analyses were by modified intention-to-treat. Overall, 621 patients were enrolled. After 254 patients, a pre-specified interim analysis resulted in several protocol changes, including a lower blood pressure inclusion criterion as well as a new allocation scheme of 2:1:2:1, overweighting both placebo, and the 5 mg/h dose. TRV027 did not confer any benefit over placebo at any dose with regards to the primary composite endpoint or any of the individual components. There were no significant safety issues with TRV027.

conclusionIn this phase IIb dose-ranging AHF study, TRV027 did not improve clinical status through 30-day follow-up compared with placebo.

Indexed as

AgedAngiotensin II Type 1 Receptor BlockersDose-Response Relationship, DrugDouble-Blind MethodFemaleHeart FailureHumansInfusions, IntravenousLength of StayMaleOligopeptidesTreatment OutcomeAngiotensin II Type 1 Receptor BlockersOligopeptidesSar-Arg-Val-Tyr-Ile-His-Pro-Ala-OHAcute heart failureAngiotensin-IIBiased ligandClinical trials

Identifiers

PMID28459958
PMCPMC5837312
OpenAlexW2608624392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.